GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Canbridge Pharmaceuticals Inc (HKSE:01228) » Definitions » 5-Year Yield-on-Cost %

Canbridge Pharmaceuticals (HKSE:01228) 5-Year Yield-on-Cost % : 0.00 (As of May. 01, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Canbridge Pharmaceuticals 5-Year Yield-on-Cost %?

Canbridge Pharmaceuticals's yield on cost for the quarter that ended in Jun. 2024 was 0.00.


The historical rank and industry rank for Canbridge Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:



HKSE:01228's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.68
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Canbridge Pharmaceuticals's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Canbridge Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Canbridge Pharmaceuticals's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Canbridge Pharmaceuticals's 5-Year Yield-on-Cost % falls into.


;
;

Canbridge Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Canbridge Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Canbridge Pharmaceuticals  (HKSE:01228) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Canbridge Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Canbridge Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Canbridge Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Building 21, No. 388 Xinping Street, Unit 18, 6th Floor, Suzhou Industrial Park, Suzhou, CHN
Canbridge Pharmaceuticals Inc is a biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.
Executives
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2101 Beneficial owner
Xue James Qun 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Athos Capital Limited 2102 Investment manager
Moskey Matthew Love 2201 Interest of corporation controlled by you
Schulte-hillen Friedrich Bela 2201 Interest of corporation controlled by you
Athos Asia Event Driven Master Fund 2101 Beneficial owner
Ctx Pharma Holdings Limited 2101 Beneficial owner
Kolchinsky Anna Inge Leonore Haas 2202 Interest of your spouse
Kolchinsky Peter 2305 Beneficiary of a trust
Ra Capital Management, L.p. 2102 Investment manager
Ra Capital Healthcare Fund Gp, Llc 2201 Interest of corporation controlled by you
Ra Capital Healthcare Fund, L.p. 2101 Beneficial owner

Canbridge Pharmaceuticals Headlines

No Headlines